Departments of 1 Molecular Pharmacology and 2 Medicine and Cell Biology and 3 Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York 10461
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The potential role of caveolin-1 in apoptosis remains controversial. Here, we investigate whether caveolin-1 expression is proapoptotic or antiapoptotic using a well-defined antisense approach. We show that NIH/3T3 cells harboring antisense caveolin-1 are resistant to staurosporine-induced apoptosis, as assessed using cell morphology, DNA content, caspase 3 activation, and focal adhesion kinase cleavage. Importantly, sensitivity to apoptosis is recovered when caveolin-1 levels are restored. Conversely, recombinant stable expression of caveolin-1 in T24 bladder carcinoma cells sensitizes these cells to caspase 3 activation. Consistent with the observations using NIH/3T3 cells, downregulation of caveolin-1 in T24 cells substantially diminishes caspase 3-like activity. Loss of sensitivity to apoptotic stimulation is recovered by inhibition of the phosphatidylinositol 3-kinase pathway using LY-294002, suggesting a possible mechanism for the sensitizing effect of caveolin-1. Thus our results suggest that caveolin-1 may act as a coupling or sensitizing factor in signaling apoptotic cell death in both fibroblastic (NIH/3T3) and epithelial (T24) cells.
caveolae; caveolin; signaling
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
CAVEOLINS, a family of 21- to 24-kDa integral membrane proteins, are the principal structural components of caveolae membrane domains. Recent in vivo and in vitro studies have shown that the caveolins associate and directly interact with a variety of signaling molecules via a modular protein domain, termed the caveolin-scaffolding domain (21). More specifically, the caveolin-scaffolding domain recognizes a specific caveolin-binding motif within a given signaling protein (42, 49).
Interestingly, caveolin binding via the scaffolding domain inhibits the activity of both tyrosine and serine/threonine kinases, including Src family tyrosine kinases, epidermal growth factor receptor (EGFR), Neu, mitogen-activated protein kinase (MEK1), extracellularly regulated kinase 2 (ERK2), protein kinase C (PKC), and protein kinase A (11, 17, 34, 44, 49). Functional studies revealed that overexpression of caveolin-1 dramatically inhibits the p42/44 mitogen-activated protein kinase signaling cascade (17, 39). Hence, these results suggest that caveolin may function as a general inhibitor of protein kinases.
Although caveolin-1 is expressed in most cell types, caveolin-1 expression is downregulated or absent in oncogenically transformed NIH/3T3 cells, as well as human cancer cells (19, 32, 33, 43). Conversely, overexpression of caveolin-1 blocks anchorage-independent growth of oncogenically transformed cells (19, 33), indicating that caveolin-1 may act as a suppressor of oncogenic transformation (42). More recently, we have shown that an antisense-mediated reduction in caveolin-1 protein expression in NIH/3T3 cells is sufficient to drive oncogenic transformation and constitutively activate the p42/44 mitogen-activated protein (MAP) kinase cascade (27). Finally, the human caveolin-1 gene is localized to a suspected tumor suppressor locus (D7S522; 7q31.1), a known fragile site (FRA7G) that is deleted in many forms of cancer (20-23). Thus downregulation of caveolin-1 expression and caveolae organelles may be critical for maintaining the transformed phenotype.
Apoptosis plays a pivotal role both in
embryonic development and in maintaining homeostasis in adult
tissues. Morphologically, cells undergoing apoptosis
exhibit cytoplasmic shrinkage, nuclear condensation,
internucleosomal DNA cleavage, and cellular fragmentation (13). A central component of the death machinery is a
novel family of cysteine proteases, termed caspases (53).
Caspases are expressed as proenzymes that contain an
NH2-terminal prodomain, a large subunit (~20 kDa) and a
small subunit (~10 kDa). Upon the receipt of "death signals",
caspases become activated by proteolytic processing between their
domains. The resulting active enzyme complex is a heterotetramer of
two large and two small subunits. Activated caspases subsequently
cleave multiple cellular proteins, including focal adhesion kinase
(FAK), nuclear lamins, PKC, DFF45/ICAD, Bcl-2, and poly (ADP-ribose)
polymerase (PARP), etc., leading to the demise of the cell
(12).
The potential role of caveolin-1 in apoptosis remains controversial. Using ceramide as a stimulus, Zundel and colleagues (56) observed that caveolin-1 expression in Rat-1 fibroblasts acts as a facilitator of ceramide-induced cell death. However, these authors used only cell morphology as a criterion for cell death, and they did not directly show that these effects were due to apoptosis; as a consequence, they did not use the word "apoptosis" to characterize the cell death that they observed (56). In contrast, Timme and colleagues (54) have now shown that caveolin-1 is a suppressor of c-myc-induced apoptosis in LNCaP cells, a human epithelial prostate cancer-derived cell line. Similarly, this group used only morphological criteria to assess cell death. Thus contradictory evidence has now been presented that caveolin-1 is both a facilitator and a suppressor of cell death in different contexts.
To address this discrepancy, we used a third independent apoptotic stimulus (staurosporine treatment, rather than ceramide or c-myc) to assess the potential role of caveolin-1 in apoptosis in two distinct cell lines, NIH/3T3 fibroblasts and T24 bladder carcinoma cells. In addition to morphological criteria, we used a variety of quantitative biochemical assays to directly assess apoptosis, such as DNA content, caspase 3 activity, and FAK cleavage. Our results are consistent with that idea that 1) caveolin-1 generally plays a proapoptotic role in both fibroblasts (NIH/3T3) and epithelial cells (T24), and 2) the antiapoptotic effects of caveolin-1 that were previously observed may be relevant only for myc-induced apoptosis.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Materials.
A monoclonal antibody directed against caveolin-1 (MAb clone 2297;
recognizing residues 61-71; Ref. 48) was kindly
provided by Dr. Roberto Campos-Gonzalez (Transduction Laboratories,
Lexington, KY). Reagents and other supplies were obtained from the
following commercial sources: RNase A and anti--actin MAb (Sigma
Chemical, St. Louis, MO); FAK MAb (Transduction Laboratories); anti-Akt and anti-phospho-Akt rabbit polyclonal antibodies (New England Biolabs,
Beverly, MA); staurosporine (Biomol Research Laboratories, Plymouth
Meeting, PA); ApoAlert caspase 3 assay kit (Clontech Laboratories, Palo
Alto, CA); KT-5720 (Alexis Biochemicals, San Diego, CA); hygromycin B
and N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone (z-VAD-fmk; CalBiochem, La Jolla, CA); propidium iodide (PI) and diamidinophenylindole (DAPI; Molecular Probes, Eugene, OR);
and bicinchoninic acid (BCA) protein assay kit (Pierce, Rockford, IL).
Cell culture and generation of stable cell lines. Normal NIH/3T3 cells were grown in DMEM (GIBCO BRL) with 10% heat-inactivated donor bovine calf serum (normal growth medium). NIH/3T3 cells harboring antisense caveolin-1 (Cav-1-AS) were generated by cotransfection of NIH/3T3 cells with an expression vector, pCAGGS, encoding the murine caveolin-1 inserted in the antisense orientation, and a plasmid, pCB7, containing hygromycin resistance gene, as we described previously (27). Cav-1-AS cells were selected in normal growth medium supplemented with 200 µg/ml hygromycin B (selection medium). A revertant of NIH/3T3 cells harboring Cav-1 AS (Rev-Cav-1-AS) was derived after Cav-1-AS cells were cultured in the absence of selection medium for four to six passages (27). T24 (human bladder carcinoma) cells were grown in medium 199 with 10% fetal bovine serum. Stable T24 cell lines overexpressing caveolin-1 (T24-Cav-1) were generated by transfection of T24 cells with an expression vector, pCB7, encoding caveolin-1. T24 cells harboring Cav-1-AS (T24-Cav-1-AS) were generated as described above. Cell lines harboring empty vector alone (pCB7) were also generated and served as controls. The levels of caveolin-1 expression were examined by both Western and Northern blotting, as we carefully documented previously (27).
Induction of apoptosis.
Staurosporine exposure has been used as a reliable model to induce
apoptosis in a variety of cell types (3, 4, 10, 28, 29,
45). A stock solution was made by dissolving staurosporine in
dimethyl sulfoxide (DMSO) at a concentration of 2 mM and with storage
at 20°C. For induction of apoptosis, NIH/3T3, Cav-1-AS, and
Rev-Cav-1-AS cells, as well as T24, T24-pCB7, T24-Cav-1, and T24-Cav-1-AS cells, were incubated with staurosporine for a period of
time as indicated in RESULTS. Controls were treated with
vehicle alone (0.05% DMSO).
Immunoblot analysis. The expression levels of caveolin-1 and FAK were determined by Western blotting. Briefly, cells were solubilized with SDS-sample buffer that contained 0.125 M Tris · HCl (pH 6.8), 2% (wt/vol) SDS, 5% (vol/vol) 2-mercaptoethanol, and 10% (vol/vol) glycerol in double distilled water. After being boiled for 4 min, proteins were separated by SDS-PAGE and electrotransferred to nitrocellulose membranes for immunoblotting using enhanced chemiluminescence. Before loading, the protein concentration of the samples was measured using the BCA method with bovine serum albumin as the standard.
Caspase 3-like activity assay. Caspase 3-like activity was assessed using a slightly modified ApoAlert CPP32/caspase 3 fluorescent assay. Briefly, after treatment with staurosporine, incubation medium was removed and the cells were lysed for 10 min in ice-cold lysis buffer that contained 20 mM Tris · HCl (pH 7.4), 137 mM NaCl, 1% Nonidet P-40, 10% glycerol, 1 µg/ml aprotinin, 1 µM leupeptin, and 1 mM phenylmethylsulfonyl fluoride (PMSF). Total cell lysates (10 µg each) were incubated at 37°C for 60 min in enzyme assay buffer that contained 20 mM HEPES (pH 7.5), 10% glycerol, 2 mM dithiothreitol, 1 mM PMSF, and 100 µM caspase 3 substrate, N-acetyl-Asp-Glu-Val-Asp (DEVD)-7-amino-4-methyl coumarin (AMC). The reaction was terminated by adding 1 ml of deionized H2O. Fluorescence was measured with an LS50B luminescence spectrometer (Perkin Elmer, Norwalk, CT) equipped with a 380-nm excitation filter and a 460-nm emission filter. To assess specific caspase 3-like activity, a parallel set of cell lysates was preincubated with 30 µM caspase 3 inhibitor, DEVD-aldehyde (CHO), at 37°C for 30 min and then incubated with caspase 3 substrate for 60 min.
Determination of DNA content by flow cytometry.
After treatment with staurosporine, 5 × 105 cells
were isolated using trypsin-EDTA and then fixed with 70% ethanol at
20°C overnight. Cells were pelleted by centrifugation at 200 g for 5 min, and the 70% ethanol was discarded. Cells were
then resuspended in DNA extraction buffer (0.2 M phosphate citrate
buffer, pH 7.8) for 30 min at 37°C, followed by centrifugation at
1,500 g for 10 min. Cells were then resuspended in a PI
solution (50 µg/ml in PBS) that contained 50 µg/ml RNase A and
0.1% (vol/vol) Triton X-100 and incubated in the dark at room
temperature for 30 min. The DNA content of the cells was then analyzed
using the FACScan immunocytometry system (Becton Dickinson, San Jose,
CA) (7).
Nuclear morphology visualized by DAPI staining. NIH/3T3, Cav-1-AS, and Rev-Cav-1-AS cells (pretreated with or without staurosporine) were carefully washed once with PBS, fixed with 3.7% formaldehyde at room temperature for 5 min, and then stained with DAPI (1 µg/ml in PBS) for 10 min. Nuclear morphology was examined with an Olympus IX70 fluorescent microscope equipped with a photometric charge-coupled device camera that contained a DAPI channel.
Electron microscopy. Transmission electron microscopy was performed as described previously by our laboratory. Samples were fixed with glutaraldehyde, postfixed with osmium tetroxide, and stained with uranyl acetate and lead citrate (as detailed in Refs. 36 and 46). Samples were examined under the Philips 410 transmission electron microscope.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Staurosporine-induced apoptosis in NIH/3T3 cells. Staurosporine, a potent inhibitor of diverse protein kinases, is an extraordinarily potent antiproliferative agent and a commonly used apoptotic inducer. To assess a potential role for caveolin-1 in promoting apoptosis, we first developed an apoptotic model system employing staurosporine-treated NIH/3T3 cells. Normal NIH/3T3 cells contain numerous caveolae and endogenously express both caveolins-1 and -2 (32, 47).
As shown in Fig. 1A, treatment of NIH/3T3 cells with staurosporine (1 µM) from 0 to 24 h resulted in a time-dependent change in cell shape and size, an early event in apoptosis (13). Shrinkage first appeared in the cell periphery after a 30-min treatment and became more evident after 2 h (Fig. 1A, b and d). After 6 h of treatment, all cells appeared round in shape with spider-like projections, and, by 24 h, some cells began to detach from the plate (Fig. 1A, e and f). The plasma membrane remained intact until 24 h of treatment, as assessed by trypan blue exclusion. Interestingly, focal adhesion sites remained unchanged until after 1 h of treatment and disappeared after 2 h of incubation with staurosporine (Fig. 1A, b and c), when proteolytic cleavage of FAK started to occur (Fig. 2B).
|
|
Time-dependent activation of caspase 3-like activity by staurosporine. Figure 2 shows that treatment of NIH/3T3 cells with staurosporine resulted in time-dependent activation of caspase 3-like activity. Caspase 3-like activity increased up to 2-fold after 2 h of treatment and became maximal after 6 h of treatment, resulting in ~5.8-fold activation over basal activity. The enzyme activity decreased by 10 h of treatment and returned to basal levels after 24 h of treatment (Fig. 2A). Importantly, pretreatment of cells with z-VAD-fmk (50 µM) abolished staurosporine-induced activation of caspase 3-like activity (Fig. 2C).
Activation of caspases results in proteolytic cleavage of a variety of substrates. These include FAK, nuclear lamins, PKCDownregulation of caveolin-1 inhibits apoptosis in NIH/3T3 cells. To investigate if caveolin-1 expression is required for induction of apoptosis in NIH/3T3 cells, we employed an antisense approach to generate an NIH/3T3 cell line that expresses dramatically reduced levels of caveolin-1 (see MATERIALS AND METHODS). If caveolin-1 expression is critical for mediating apoptosis, we would predict that downregulation of caveolin-1 expression in NIH/3T3 cells would block or blunt the response to apoptotic stimuli, such as staurosporine.
As we previously reported (27), NIH/3T3 cells harboring Cav-1-AS expressed substantially reduced levels of caveolin-1 (Fig. 3A). As expected, caveolae were also downregulated in these caveolin-1 antisense cells, as seen by transmission electron microscopy (Fig. 3B).
|
|
Inhibition of apoptosis by downregulation of caveolin-1 is reversible. After NIH/3T3 cells that harbor Cav-1-AS were cultured in the absence of selection media for four passages, caveolin-1 expression was restored (approaching ~70% of normal levels), due to loss of the caveolin-1 antisense vector (Fig. 3A; see Ref. 27). These results indicate that downregulation of caveolin-1 in this system is reversible.
Thus we next evaluated the ability of caveolin-1 antisense revertants to undergo apoptosis. Interestingly, the ability to undergo staurosporine-induced apoptosis was clearly restored in these cells (Rev-Cav-1-AS; Fig. 4, A and B). Treatment of the Cav-1-AS revertant cells with staurosporine resulted in nuclear condensation and fragmentation as early as 6 h (Fig. 4A). Similarly, flow cytometry analysis showed that the number of staurosporine-induced apoptotic Rev-Cav-1-AS cells increased from <3% to 6%, an ~2.8-fold increase over that which was observed in Cav-1-AS cells (P < 0.05, unpaired t-test; Fig. 4B).Downregulation of caveolin-1 inhibits caspase 3-like activity and
FAK cleavage.
Figure 5A shows that treatment
of normal NIH/3T3 cells with staurosporine dramatically increased
caspase 3-like activity by ~7.7-fold over basal levels. In contrast,
there was little or no increase in caspase 3-like activity in response
to staurosporine in NIH/3T3 cells harboring Cav-1-AS (Fig.
5A). Importantly, activation of caspase 3-like activity was
recovered when caveolin-1 expression was restored. More specifically,
treatment of Rev-Cav-1-AS cells with staurosporine caused up to an
~3.5-fold increase in caspase 3-like activity (Fig. 5A).
Virtually identical results were observed when cleavage of FAK was
monitored by Western blot analysis (Fig. 5B).
|
Recombinant expression of caveolin-1 enhances caspase 3-like activity in human T24 bladder carcinoma cells. It is now generally recognized that caveolin-1 levels are downregulated during cell transformation in a variety of cell types (49). As a consequence, we chose to recombinantly express caveolin-1 in human T24 bladder carcinoma cells because they express low levels of endogenous caveolin-1. In accordance with these findings, T24 cells contain a copy of activated H-Ras (G12V) (52), and expression of activated H-Ras (G12V) is sufficient to downregulate caveolin-1 mRNA and protein levels in NIH/3T3 cells via transcriptional control (24). With this approach, we derived stable cell lines that recombinantly express caveolin-1 (T24-Cav-1) or control cells harboring vector alone (T24-pCB7). To further confirm our previous observations that downregulation of caveolin-1 desensitizes NIH/3T3 cells to apoptosis, we also derived T24-Cav-1-AS cells.
Figure 6 shows a Western blot analysis of lysates derived from parental T24, T24-Cav-1, T24-Cav-1-AS, and T24-pCB7 cells. Note that recombinant caveolin-1 was expressed at much higher levels in T24-Cav-1 cells (~4-fold over endogenous levels) compared with T24-pCB7 cells. By comparison, the level of caveolin-1 in T24-Cav-1-AS cells was reduced by approximately fivefold compared with T24 or T24-pCB7 cells.
|
|
Inhibition of the phosphatidylinositol 3-kinase signaling pathway restores the sensitivity of cells harboring antisense caveolin-1 to apoptotic stimulation. Caveolin-1 interacts with and inactivates a number of protein kinases involved in cell growth and proliferation, such as receptor tyrosine kinases [EGFR, Neu, and platelet-derived growth factor receptor (PDGFR) (18, 19, 55)], as well as components of the p42/44 MAP kinase cascade (MEK and ERK) (19, 27). As a consequence, we reasoned that caveolin-1 may sensitize cells toward apoptosis by inactivation of kinases that participate in antiapoptotic signaling pathways, such as phosphatidylinositol 3-kinase (PI 3-kinase)/Akt/protein kinase B (PKB).
To assess whether LY-294002 was able to block the PI 3-kinase signaling pathway in T24 cells, we first treated T24 cells with PDGF in the presence or absence of LY-294002. Figure 8A shows that inhibition of PI 3-kinase by LY-294002 blocked PDGF-induced activation of Akt/PKB as assessed by Akt/PKB phosphorylation, demonstrating that treatment of T24 cells with LY-294002 was able to block the PI 3-kinase/Akt/PKB antiapoptotic signaling pathway.
|
Inhibition of the p42/44 MAP kinase pathway does not restore the
sensitivity of cells harboring Cav-1-AS to apoptotic stimulation.
To evaluate whether loss of sensitivity to apoptosis induced by
downregulated caveolin-1 resulted from its action on the p42/44 MAP
kinase signaling pathway (19, 27), NIH/3T3 Cav-1-AS cells were pretreated with a specific MEK1 inhibitor, PD-98059, for 1 h,
followed by staurosporine treatment. Consistent with our above results,
Fig. 9A shows that inhibition
of PI 3-kinase by LY-294002 substantially increased caspase 3-like
activity by 2.8-fold over control in response to staurosporine
stimulation in NIH/3T3 Cav-1-AS cells. By comparison, inhibition of
MEK1 by PD-98059 had little or no effect on staurosporine-induced
caspase 3-like activity (1.1-fold over control).
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The decision to survive and proliferate or to commit to apoptosis is essential for normal embryonic development and maintaining tissue homeostasis. This process is determined by the net balance between anti- and proapoptotic signals that are linked in a tightly regulated manner (25). Unless provided with specific survival signals, the default pathway may lead to apoptosis.
A large body of evidence suggests that caveolin-1, a putative tumor suppressor, interacts with and inactivates a number of signaling molecules along survival/proliferation pathways, such as EGFR (19), PDGFR (55), Neu (18), Src (34), Raf (19), MEK1 (19, 27), and Erk (19, 27). These results imply that caveolin-1 expression may sensitize cells toward apoptosis. However, this hypothesis remains untested.
In the present study, we have clearly demonstrated that caveolin-1 plays a critical role in regulating apoptosis. NIH/3T3 fibroblasts that express substantially reduced levels of caveolin-1 are highly resistant to apoptosis, as judged by nuclear morphology, flow cytometry, and caspase 3-like activity. Importantly, the sensitivity of these NIH/3T3 cells to proapoptotic stimulation is recovered when caveolin-1 levels are restored. In addition, the proapoptotic activity of caveolin-1 was also observed with the use an epithelial cell line, namely, T24 human bladder carcinoma cells. Recombinant expression of caveolin-1 in these cells substantially enhanced their sensitivity to apoptotic stimulation. Thus our results suggest that caveolin-1 expression may provide a coupling or sensitizing function in signaling cell death.
The PDGF-activated PI 3-kinase/PKB/Akt signaling cascade is a well-characterized growth factor pathway that promotes cell survival and inhibits cell death (14). In this survival cascade, PI 3-kinase and Akt are critical factors; suppression of Akt activity by recombinant expression of dominant-negative Akt or of a mutant Akt consisting only of the pleckstrin homology domain abrogates growth factor-induced survival signals (16, 51). Several recent reports have demonstrated that proteins involved in the apoptotic process, including BAD (15) and caspase 9 (8), are targets of Akt. Phosphorylation and inactivation of these proteins by Akt protects cells from apoptosis.
What is the mechanism by which caveolin-1 can promote apoptosis? Caveolin-mediated inactivation of growth/proliferation signals is an attractive explanation. Here, we observed that blocking PI 3-kinase-mediated survival signals restores sensitivity to proapoptotic stimulation in cells harboring the caveolin-1 antisense vector. These results suggest that the proapoptotic function of caveolin-1 may result from its inhibitory action on PI 3-kinase. Indeed, consistent with our observations, Zundel and colleagues (56) have recently shown that ceramide (a known proapoptotic inducer) inactivates PI 3-kinase by recruiting caveolin-1 into receptor tyrosine kinase/PI 3-kinase complexes and that overexpression of caveolin-1 can inhibit the activity of PI 3-kinase. These results suggest that the proapoptotic activity of caveolin-1 expression is mediated via suppression of growth factor-stimulated survival pathways. In support of these observations, we have previously shown that caveolin-1 expression inhibits the growth factor-activated p42/44 MAP kinase signaling cascade in vivo (17, 39).
Another explanation may be the effect of caveolin-1 on the organization and assembly of anti- and proapoptotic signaling molecules at the cell surface. It has been proposed that caveolae function as message centers that compartmentalize signaling molecules at the cell surface (1, 35). A variety of signaling molecules that mediate anti- and proapoptotic signals are dramatically enriched in caveolae or caveolin-enriched microdomains (31, 36, 38, 40, 41, 50). Disruption of caveolae also affects proliferative signal transduction (26, 38).
More recent evidence has demonstrated that proapoptotic signaling
molecules [such as tumor necrosis factor (TNF) receptor 1 and CD36]
reside within caveolae-related membrane domains and that disruption of
these organelles (via cholesterol-binding drugs) specifically blocks
TNF--induced apoptosis (31). These results are
consistent with our current findings that disruption of caveolae organelles via antisense ablation of caveolin-1 expression blocks staurosporine-induced apoptosis.
Nerve growth factor-mediated activation of p75 neurotrophin receptor signaling in cultured oligodendrocytes leads to apoptosis (9). In addition, the role of p75 neurotrophin receptor in cellular apoptosis has been critically reevaluated by using genetically engineered mice that lack p75 neurotrophin receptor or neurotrophin brain-derived neurotrophic factor, or both (2). The results provided firm evidence that the p75 neurotrophin receptor mediates apoptosis in vivo. Recent studies have revealed that the p75 neurotrophin receptor is located within caveolae and caveolae-related domains and forms a physical complex with caveolin-1 in a heterologous expression system (5, 6). Upon ligand binding, it is likely that the p75 neurotrophin receptor utilizes caveolar sphingomyelin as a substrate to generate ceramide and induces apoptosis. Interleukin-1 receptor seems to adopt similar apoptotic signaling via caveolae (37). Thus caveolae may play a proapoptic role by providing a common organized platform for death receptors to induce cell apoptosis.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank Dr. Roberto Campos-Gonzalez for generously providing caveolin-1-specific monoclonal antibodies and Dr. Michael Cammer and Carolyn Marks for assistance with cell and nuclear morphology studies.
![]() |
FOOTNOTES |
---|
This work was supported by grants from the National Institutes of Health, the Muscular Dystrophy Association, the American Heart Association, and the Komen Breast Cancer Foundation (to M. P. Lisanti). P. Lee and R. N. Kitsis were supported by National Heart, Lung, and Blood Institute Grants R01-HL-60665 and R01-HL-61550 (to R. N. Kitsis).
M. P. Lisanti is the recipient of a Hirschl/Weil-Caulier Career Scientist Award.
Address for reprint requests and other correspondence: M. P. Lisanti, Dept. of Molecular Pharmacology, Albert Einstein College of Medicine, 1300 Morris Park Ave., Bronx, NY 10461 (E-mail: lisanti{at}aecom.yu.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 14 August 2000; accepted in final form 27 October 2000.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Anderson, RGW
Caveolae: where incoming and outgoing messengers meet.
Proc Natl Acad Sci USA
90:
10909-10913,
1993[Abstract].
2.
Bamji, SX,
Majdan M,
Pozniak CD,
Belliveau DJ,
Aloyz R,
Kohn J,
Causing CG,
and
Miller FD.
The p75 neurotrophin receptor mediates neuronal apoptosis and is essential for naturally occurring sympathetic neuron death.
J Cell Biol
140:
911-923,
1998
3.
Bellosta, P,
Zhang Q,
Goff SP,
and
Basilico C.
Signaling through the ARK tyrosine kinase receptor protects from apoptosis in the absence of growth stimulation.
Oncogene
15:
2387-2397,
1997[ISI][Medline].
4.
Bertrand, R,
Solary E,
O'Connor P,
Kohn KW,
and
Pommier Y.
Induction of a common pathway of apoptosis by staurosporine.
Exp Cell Res
211:
314-321,
1994[ISI][Medline].
5.
Bilderback, TR,
Gazula VR,
Lisanti MP,
and
Dobrowsky RT.
Caveolin interacts with Trk A and p75(NTR) and regulates neurotrophin signaling pathways.
J Biol Chem
274:
257-263,
1999
6.
Bilderback, TR,
Grigsby RJ,
and
Dobrowsky RT.
Association of p75(NTR) with caveolin and localization of neurotrophin-induced sphingomyelin hydrolysis to caveolae.
J Biol Chem
272:
10922-10927,
1997
7.
Bonifacino, JS,
Dasso M,
Harford JB,
Lippincott-Schwartz J,
and
Yamada KM
(Editors).
Current Protocols in Cell Biology. New York: Wiley, 1998.
8.
Cardone, MH,
Roy N,
Stennicke HR,
Salvesen GS,
Franke TF,
Stanbridge E,
Frisch S,
and
Reed JC.
Regulation of cell death protease caspase-9 by phosphorylation.
Science
282:
1318-1321,
1998
9.
Casaccia-Bonnefil, P,
Carter BD,
Dobrowsky RT,
and
Chao MV.
Death of oligodendrocytes mediated by the interaction of nerve growth factor with its receptor p75.
Nature
383:
716-719,
1996[ISI][Medline].
10.
Castelli, JC,
Hassel BA,
Maran A,
Paranjape J,
Hewitt JA,
Li XL,
Hsu YT,
Silverman RH,
and
Youle RJ.
The role of 2'-5' oligoadenylate-activated ribonuclease L in apoptosis.
Cell Death Differ
5:
313-320,
1998[ISI][Medline].
11.
Couet, J,
Sargiacomo M,
and
Lisanti MP.
Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities.
J Biol Chem
272:
30429-30438,
1997
12.
Cryns, V,
and
Yuan J.
Proteases to die for.
Genes Dev
12:
1551-1570,
1998
13.
Darzynkiewicz, Z,
Juan G,
Li X,
Gorczyca W,
Murakami T,
and
Traganos F.
Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis).
Cytometry
27:
1-20,
1997[ISI][Medline].
14.
Datta, SR,
Brunet A,
and
Greenberg ME.
Cellular survival: a play in three Akts.
Genes Dev
13:
2905-2927,
1999
15.
Datta, SR,
Dudek H,
Tao X,
Masters S,
Fu H,
Gotoh Y,
and
Greenberg ME.
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery.
Cell
91:
231-241,
1997[ISI][Medline].
16.
Dudek, H,
Datta SR,
Franke TF,
Birnbaum MJ,
Yao R,
Cooper GM,
Segal RA,
Kaplan DR,
and
Greenberg ME.
Regulation of neuronal survival by the serine-threonine protein kinase Akt.
Science
275:
661-665,
1997
17.
Engelman, JA,
Chu C,
Lin A,
Jo H,
Ikezu T,
Okamoto T,
Kohtz DS,
and
Lisanti MP.
Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain.
FEBS Lett
428:
205-211,
1998[ISI][Medline].
18.
Engelman, JA,
Lee RJ,
Karnezis A,
Bearss DJ,
Webster M,
Siegel P,
Muller WJ,
Windle JJ,
Pestell RG,
and
Lisanti MP.
Reciprocal regulation of Neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer.
J Biol Chem
273:
20448-20455,
1998
19.
Engelman, JA,
Wycoff CC,
Yasuhara S,
Song KS,
Okamoto T,
and
Lisanti MP.
Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth.
J Biol Chem
272:
16374-16381,
1997
20.
Engelman, JA,
Zhang XL,
Galbiati F,
and
Lisanti MP.
Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cav-1, -2, and -3). Cav-1 and Cav-2 genes map to a known tumor suppressor locus (6-A2/7q31).
FEBS Lett
429:
330-336,
1998[ISI][Medline].
21.
Engelman, JA,
Zhang XL,
Galbiati F,
Volonte D,
Sotgia F,
Pestell RG,
Minetti C,
Scherer PE,
Okamoto T,
and
Lisanti MP.
Molecular genetics of the caveolin gene family: implications for human cancers, diabetes, Alzheimer's disease, and muscular dystrophy.
Am J Hum Genet
63:
1578-1587,
1998[ISI][Medline].
22.
Engelman, JA,
Zhang XL,
and
Lisanti MP.
Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers.
FEBS Lett
436:
403-410,
1998[ISI][Medline].
23.
Engelman, JA,
Zhang XL,
and
Lisanti MP.
Sequence and detailed organization of the human caveolin-1 and -2 genes located near the D7S522 locus (7q31.1). Methylation of a CpG island in the 5' promoter region of the caveolin-1 gene in human breast cancer cell lines.
FEBS Lett
448:
221-230,
1999[ISI][Medline].
24.
Engelman, JA,
Zhang XL,
Razani B,
Pestell RG,
and
Lisanti MP.
p42/44 MAP kinase-dependent and -independent signaling pathways regulate caveolin-1 gene expression. Activation of Ras-MAP kinase and PKA signaling cascades transcriptionally downregulates caveolin-1 promoter activity.
J Biol Chem
274:
32333-32341,
1999
25.
Evan, G,
and
Littlewood T.
A matter of life and cell death.
Science
281:
1317-1321,
1998
26.
Furuchi, T,
and
Anderson RGW
Cholesterol depletion of caveolae causes hyperactivation of extracellular signal-related kinase (ERK).
J Biol Chem
273:
21099-21104,
1998
27.
Galbiati, F,
Volonte D,
Engelman JA,
Watanabe G,
Burk R,
Pestell R,
and
Lisanti MP.
Targeted down-regulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade.
EMBO J
17:
6633-6648,
1998
28.
Godard, T,
Deslandes E,
Lebailly P,
Vigreux C,
Sichel F,
Poul JM,
and
Gauduchon P.
Early detection of staurosporine-induced apoptosis by comet and annexin V assays.
Histochem Cell Biol
112:
155-161,
1999[ISI][Medline].
29.
Goswami, R,
Kilkus J,
Dawson SA,
and
Dawson G.
Overexpression of akt (protein kinase B) confers protection against apoptosis and prevents formation of ceramide in response to pro-apoptotic stimuli.
J Neurosci Res
57:
884-893,
1999[ISI][Medline].
30.
Kase, H,
Iwahashi K,
Nakanishi S,
Matsuda Y,
Yamada K,
Takahashi M,
Murakata C,
Sato A,
and
Kaneko M.
K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases.
Biochem Biophys Res Commun
142:
436-440,
1987[ISI][Medline].
31.
Ko, YG,
Lee JS,
Kang YS,
Ahn JH,
and
Seo JS.
TNF--mediated apoptosis is initiated in caveolae-like domains.
J Immunol
162:
7217-7223,
1999
32.
Koleske, AJ,
Baltimore D,
and
Lisanti MP.
Reduction of caveolin and caveolae in oncogenically transformed cells.
Proc Natl Acad Sci USA
92:
1381-1385,
1995[Abstract].
33.
Lee, SW,
Reimer CL,
Oh P,
Campbel DB,
and
Schnitzer JE.
Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells.
Oncogene
16:
1391-1397,
1998[ISI][Medline].
34.
Li, S,
Couet J,
and
Lisanti MP.
Src tyrosine kinases, G subunits and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases.
J Biol Chem
271:
29182-29190,
1996
35.
Lisanti, MP,
Scherer P,
Tang ZL,
and
Sargiacomo M.
Caveolae, caveolin and caveolin-rich membrane domains: a signalling hypothesis.
Trends Cell Biol
4:
231-235,
1994.
36.
Lisanti, MP,
Scherer PE,
Vidugiriene J,
Tang ZL,
Hermanoski-Vosatka A,
Tu YH,
Cook RF,
and
Sargiacomo M.
Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease.
J Cell Biol
126:
111-126,
1994[Abstract].
37.
Liu, J,
Oh P,
Horner T,
Rogers RA,
and
Schnitzer JE.
Organized endothelial cell signal transduction in caveolae.
J Biol Chem
272:
7211-7222,
1997
38.
Liu, J,
Razani B,
Tang S,
Terman BI,
Ware JA,
and
Lisanti MP.
Angiogenesis activators and inhibitors differentially regulate caveolin-1 expression and caveolae formation in vascular endothelial cells. Angiogenesis inhibitors block vascular endothelial growth factor-induced down-regulation of caveolin-1.
J Biol Chem
274:
15781-15785,
1999
39.
Liu, P,
and
Anderson RGW
Compartmentalized production of ceramide at the cell surface.
J Biol Chem
270:
27179-27185,
1995
40.
Liu, P,
Ying Y,
Ko YG,
and
Anderson RGW
Localization of the PDGF-stimulated phosphorylation cascade to caveolae.
J Biol Chem
271:
10299-10303,
1996
41.
Mineo, C,
James GL,
Smart EJ,
and
Anderson RGW
Localization of EGF-stimulated Ras/Raf-1 interaction to caveolae membrane.
J Biol Chem
271:
11930-11935,
1996
42.
Okamoto, T,
Schlegel A,
Scherer PE,
and
Lisanti MP.
Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane.
J Biol Chem
273:
5419-5422,
1998
43.
Racine, C,
Belanger M,
Hirabayashi H,
Boucher M,
Chakir J,
and
Couet J.
Reduction of caveolin 1 gene expression in lung carcinoma cell lines.
Biochem Biophys Res Commun
255:
580-586,
1999[ISI][Medline].
44.
Razani, B,
Rubin CS,
and
Lisanti MP.
Regulation of cAMP-mediated signal transduction via interaction of caveolins with the catalytic subunit of protein kinase A.
J Biol Chem
274:
26353-26360,
1999
45.
Rubin, LL.
Neuronal cell death: when, why and how.
Br Med Bull
53:
617-631,
1997[Abstract].
46.
Sargiacomo, M,
Sudol M,
Tang ZL,
and
Lisanti MP.
Signal transducing molecules and GPI-linked proteins form a caveolin-rich insoluble complex in MDCK cells.
J Cell Biol
122:
789-807,
1993[Abstract].
47.
Scherer, PE,
Lewis RY,
Volonte D,
Engelman JA,
Galbiati F,
Couet J,
Kohtz DS,
van Donselaar E,
Peters P,
and
Lisanti MP.
Cell-type and tissue-specific expression of caveolin-2. Caveolins 1 and 2 co-localize and form a stable hetero-oligomeric complex in vivo.
J Biol Chem
272:
29337-29346,
1997
48.
Scherer, PE,
Tang ZL,
Chun MC,
Sargiacomo M,
Lodish HF,
and
Lisanti MP.
Caveolin isoforms differ in their N-terminal protein sequence and subcellular distribution: identification and epitope mapping of an isoform-specific monoclonal antibody probe.
J Biol Chem
270:
16395-16401,
1995
49.
Smart, EJ,
Graf GA,
McNiven MA,
Sessa WC,
Engelman JA,
Scherer PE,
Okamoto T,
and
Lisanti MP.
Caveolins, liquid-ordered domains, and signal transduction.
Mol Cell Biol
19:
7289-7304,
1999
50.
Smart, EJ,
Ying Y,
Mineo C,
and
Anderson RGW
A detergent free method for purifying caveolae membrane from tissue cultured cells.
Proc Natl Acad Sci USA
92:
10104-10108,
1995[Abstract].
51.
Songyang, Z,
Baltimore D,
Cantley LC,
Kaplan DR,
and
Franke TF.
Interleukin 3-dependent survival by the Akt protein kinase.
Proc Natl Acad Sci USA
94:
11345-11350,
1997
52.
Taparowsky, E,
Suard Y,
Fasano O,
Shimizu K,
Goldfarb M,
and
Wigler M.
Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change.
Nature
300:
762-765,
1982[ISI][Medline].
53.
Thornberry, NA,
and
Lazebnik Y.
Caspases: enemies within.
Science
281:
1312-1316,
1998
54.
Timme, TL,
Goltsov A,
Tahir S,
Li L,
Wang J,
Ren C,
Johnston RN,
and
Thompson TC.
Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis.
Oncogene
19:
3256-3265,
2000[ISI][Medline].
55.
Yamamoto, M,
Toya Y,
Jensen RA,
and
Ishikawa Y.
Caveolin is an inhibitor of platelet-derived growth factor receptor signaling.
Exp Cell Res
247:
380-388,
1999[ISI][Medline].
56.
Zundel, W,
Swiersz LM,
and
Giaccia A.
Caveolin 1-mediated regulation of receptor tyrosine kinase-associated phosphatidylinositol 3-kinase activity by ceramide.
Mol Cell Biol
20:
1507-1514,
2000